TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Efficacy of Botox in the Treatment of Social Anxiety Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* primary diagnosis of social anxiety disorder~* women of childbearing potential on an acceptable form of birth control and are not pregnant or lactating~Exclusion Criteria:~* has ever been treated with botulinum toxin A~* has another Axis I diagnosis within in the 6-months prior to screening~* history of substance abuse within 2-months of screening~* current or recent suicidality~* scoring greater than 2 on Beck Depression Inventory (BDI) suicidality question~* psychotic or bipolar disorder~* unstable medical condition~* changes in medication or psychotherapy treatment in the month prior to screening~* significant risk of committing homicide

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Open-label (Type: OTHER): 10 participants will be recruited for an open-label study. All will receive the active medication and complete depression and anxiety surveys at baseline, 4-weeks, and 8-weeks post injection. All participants will receive botulinum toxin A.
- Double-Blind (Type: PLACEBO_COMPARATOR): 30 participants will be recruited for a double-blind, comparison study. Participants will be randomized to the active or control groups. Each will receive an injection (active medication or placebo) and will complete a depression and anxiety survey at baseline, 4-weeks and 8-weeks post injection. Participants in the active group will receive botulinum toxin A; participants in the control group will receive a placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Furosemide vs Placebo for Brain Relaxation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Inclusion criteria include:~  * ASA PS I-III~ * Age 18 or older~ * Presenting for elective resection of primary or metastatic supratentorial brain tumor(s)~Exclusion Criteria:~* • ASA PS IV or V~  * Age less than 18~ * Emergency surgery due to severely elevated ICP/impending brainstem herniation~ * Concurrent use of diuretics for any indication~ * Infratentorial/posterior fossa/cerebellar tumor resection~ * Moderate/severe cardiac disease with limitation in contractility as measured by preoperative echocardiogram (EF \< 30%)~ * Severe pulmonary hypertension as measured and/or observed by preoperative studies~ * Preoperative use of steroids (within 6 months, including those on standing doses)~ * Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Furosemide (Type: ACTIVE_COMPARATOR): Furosemide 0.3 mg/kg
- Placebo (Type: PLACEBO_COMPARATOR): Up to 5 mL saline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: REWORD-HF REverse WOrsening Renal Function in Decompensated Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria~On admission (screening)~* Informed consent~* Age 18-80 years~* NYHA class III - IV~* Signs of pulmonary (pulmonary rales, and interstitial oedema or pleural effusion on chest Xray) and/or systemic congestion (pitting ankle oedema and enlarged liver or ascites and neck vein distension ≥ 7 cm) and weight gain ≥ 2 kg during the previous week~* Glomerular filtration rate ≥ 30 ml/min~* BNP increased \>400 pg/ml (diagnostic cut-off for ADCHF), as confirmatory diagnostic test)~  24 hours after admission (randomization)~* Persistent signs of pulmonary (pulmonary rales, interstitial oedema or pleural effusion on chest Xray) and/or systemic congestion (ankle oedema, enlarged liver or ascites, neck vein distension ≥ 7 cm)~* Serum creatinine or urine output criteria indicative of modified RIFLE (AKI: risk) class at least 1 (increase x 1.5 in serum creatinine or decrease \> 25% in GFR or urine output \< 0.5 ml/Kg/h for more than 6 hours) 29-30 during diuretic infusion~Exclusion criteria~* Chronic kidney disease stage 4-5 (GFR \< 30 ml/min)~* Acute coronary syndromes~* Systolic blood pressure \<90 mm Hg/need for intravenous inotropes~* Hematocrit \> 45%~* Unattainable venous access~* Contraindications to anticoagulation by heparin~* Systemic infection~* Heart transplant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Infusional drug treatment (Type: ACTIVE_COMPARATOR): Diuretics or diuretics plus fixed low dose dopamine infusion
- Ultrafiltration (Type: EXPERIMENTAL): Device: Ultrafiltration appliance Sessions of 8 h UF are conducted on 2 subsequent days in the first 48 hours after randomization; a third session is performed on day 3 in case of persistent congestion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Computed Tomography

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a combination of diabetes mellitus (type I or II) and renal impairment who are referred for a contrast-enhanced CT examination.~Exclusion Criteria:~* Concurrent administration of potentially nephroprotective or nephrotoxic drugs is not permitted.~* Patients undergoing dialysis or kidney transplantation will not be included.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Iodixanol 320-Arm 1 (Type: ACTIVE_COMPARATOR): Iodixanol 320 mg I/mL
- Iopamidol 300-Arm 2 (Type: ACTIVE_COMPARATOR): Iopamidol 300 mg I/mL

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Advanced Robotic Training With Additional Degrees of Freedom: Towards a Free-walking System

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Lower extremity weakness due to stroke~* minor functional impairment (MRC \< 5)~* ability and willingness to participate~Exclusion Criteria:~* severe spasticity of the lower extremities~* severe dementia~* severe depression~* any other contraindications against Lokomat training~* body weight \> 135 kg

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lokomat Pro (Type: ACTIVE_COMPARATOR): gait robot established on the market
- Lokomat Pro FreeD (Type: EXPERIMENTAL): gait robot based on the Lokomat Pro with changes in guidance of the hip, approved for the Swiss market

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: The Influence of Probiotics on Vancomycin-Resistant Enterococcus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* VRE positive patients with GI colonization~Exclusion Criteria:~* Age less than 18 years~* Patients who have had a bone marrow transplant~* Extreme short bowel patients (less than 100 cm small bowel remaining)~* Patients with active VRE infection but no GI colonization~* Patients unable to eat and have no feeding access~* Patients who do not have a power of attorney to give consent if they are unable to

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): VRE positive patients
- 2 (Type: PLACEBO_COMPARATOR): VRE positive patients

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: An Evaluation Of PF-03715455 In Moderate To Severe Uncontrolled Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with a physician documented history or diagnosis of persistent asthma (according to GINA, 2014 definition of asthma),~* Pre bronchodilator FEV1 of greater than or equal to 50 and less that 80% of predicted.~* Subjects defined as GINA Step 4 on a stable dose of either fluticasone/salmeterol combination therapy, or budesonide/formoterol combination therapy or mometasone/formoterol combination therapy.~* Subjects who are defined as uncontrolled as evidenced by; Juniper Asthma Control Questionnaire (5 item version, ACQ) score greater than or equal to 1.5 and less than or equal to 3.0)~Exclusion Criteria:~* Subjects diagnosed with chronic pulmonary disease (COPD) and/or other chronic pulmonary diseases (eg, Occupational asthma, pulmonary fibrosis, bronchiectasis, Allergic bronchopulmonary aspergillosis (ABPA), pneumoconiosis, sarcoidosis, tuberculosis).~* Subjects who are current smokers.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Matched blinded placebo
- PF-03715455 (Type: EXPERIMENTAL): PF-03715455

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Mechanisms of Dysfunction and the Influence of Exercise on Cardiac and Musculoskeletal Function

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Fontan Patients:~1. Patients who have had the Fontan cardiac procedure~2. 10-16 years of age~3. Written Informed Consent~Healthy Controls:~1. 10 - 16 years of age~2. Written Informed Consent~Exclusion Criteria:~Fontan Patients:~1. Contraindication to exercise~2. Physically active (i.e., ≥ 60 minute of moderate-vigorous activity) (Strong et al., 2005)~3. Patients in whom MRI is contraindicated (e.g. pacemaker, ocular metal, claustrophobia, tattoos)~4. Patients with a known allergy to gadolinium.~5. Patients with a history of allergic disposition or have anaphylactic reactions~6. Moderate-to-severe renal impairment (defined as having a GFR/ eGFR \< 60 mL/min)~7. Have Sickle Cell anemia~8. Known pregnancy, or breast feeding~9. Patient is uncooperative during a MRI without sedation or anesthesia~Healthy Controls:~1. Contraindication to exercise~2. Physically active (i.e., ≥ 60 minute of moderate-vigorous activity) (Strong et al., 2005)~3. Patients in whom MRI is contraindicated (e.g. pacemaker, ocular metal, claustrophobia, tattoos, pregnancy)~4. Patient is uncooperative during a MRI without sedation or anesthesia

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 16 Years
- Healthy Volunteers: t

Study Arms:
- Fontan Patients (Type: EXPERIMENTAL): Fontan patients who are monitored at the Hospital for Sick Children (SickKids) will undergo an exercise program
- Healthy Controls (Type: NO_INTERVENTION): Healthy age-matched adolescents

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: The Role of HMGB-1 in Chronic Stroke

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients admitted to the stroke service at Northshore and LIJ Medical Centers~* Patients 18 years of age or older~Exclusion Criteria:~* Patients \< 18 years of age

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Role of Platelet Rich Plasma for Erectile Dysfunction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* history of mild to moderate erectile dysfunction measured by IIEF~Exclusion Criteria:~* history or prostate cancer treatment (prostatectomy, radiation, brachytherapy)

- Gender: MALE
- Minimum Age: 50 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: SHAM_COMPARATOR): All arms will have phlebotomy (blood drawn). This group will receive saline injection only.
- Platelet rich plasma (Type: EXPERIMENTAL): All arms will have phlebotomy (blood drawn). This group will receive PRP injection only.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Assessment of Penile Vibratory Stimulation Using the Viberect in Men With Mild-Moderate ED

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria~* mild-moderate erectile dysfunction based on International Index of Erectile Function (IIEF) erectile function score 13-25~Exclusion Criteria~* Men with neurological disease~* IIEF score less than 13~* Spinal cord injury~* History of priapism~* Pelvic neuropathy~* Post-prostatectomy~* Penile skin lesions or ulcers~* Inability to understand and demonstrate device use instructions

- Gender: MALE
- Minimum Age: 30 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Viberect treatment (Type: EXPERIMENTAL): Participants in this arm have documented mild to moderate ED of organic etiology and will be given the Viberect device for 4 weeks of daily home use in preparation for sexual activity. Men will be asked to use the device and attempt sexual intercourse at least 3 times weekly

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: An Open-Labeled Pilot Study of Biomarker Response Following Short-Term Exposure to Metformin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age between 18- 75 years~2. Colonic lesion that should be removed surgically:~3. 2.a. CRC that is potentially resectable and not requiring neoadjuvant treatment.~4. 2.b. Endoscopically non-resectable adenoma.~5. 2.c. Familial Adenomatous Polyposis (FAP) patient that requires colectomy or proctocolectomy.~6. Need for perioperative colonoscopy as a part of standard of care evaluation:~7. 6.a. CRC or adenoma for which the colorectal surgeon requires a preoperative colonoscopy or sigmoidoscopy for any reason, including but not limited to:~8. 6.a.a. No outside colonoscopy~9. 6.a.b. No outside pathology~10. 6.a.c. Partially obstructing tumor or~11. 6.a.d. Otherwise unsatisfactory outside colonoscopy~12. 6.a.e. Rectal cancer requiring EUS~13. 6.a.f. Second opinion on adenoma regarded as endoscopically non-resectable on outside colonoscopy; or~14. 6.b. Patient found on initial MDACC colonoscopy to have CRC or endoscopically non-resectable adenoma, most commonly patients undergoing average or high risk (familial, history of adenoma) screening colonoscopy.~15. Ability to give informed consent.~16. Diabetic patients are eligible but they may be excluded if they are taking Metformin, insulin or sulfonylureas.~Exclusion Criteria:~1. Patients with renal insufficiency defined as serum creatinine \>= 1.4 mg/dl for females and \>= 1.5 mg/dl for males~2. Pregnant or nursing women~3. A malignancy currently under active therapy~4. Unstable angina~5. Uncontrolled ischemic cardiac disease or symptomatic congestive heart failure (e.g. Class III or IV New York Heart Association's Functional Classification)~6. Current usage of Metformin~7. Current usage of insulin, sulfonylureas~8. History of lactic acidosis~9. Chronic liver disease or cirrhosis~10. Inability to give informed consent~11. Other investigational drugs within the past one year or concurrently~12. Known hypersensitivity or intolerance to Metformin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Metformin + Colon Surgery (Type: EXPERIMENTAL): Patients randomized to Metformin-ER 500 mg once daily for one week and then escalation to 1000 mg/day for the duration of the trial. The duration of the trial will be from the preoperative endoscopy till the surgery, and should be not less than 10 days and not more than 30 days.
- Colon Surgery Alone (Type: NO_INTERVENTION): Patients will not receive any study drug from the time of colonoscopy until surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: vNOTES Salpingo-oophorectomy or Bilateral Salpingectomy Compared With Laparoscopic.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Women aged between 18 and 80 years.~2. women who seek for definitive surgical sterilisation.~3. women who planed for Elective bilateral salpingectomy or Salpingo-oophorectomy for a non-malignant indication~Exclusion Criteria:~1. history of rectal surgery.~2. rectovaginal endometriosis~3. suspected malignancy~4. History of pelvic inflammatory disease.~5. active lower genital tract infection.~6. Virgo women~7. pregnancy~8. Failure to provide written informed consent prior to surgery

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Study group: vNOTES (Type: EXPERIMENTAL): Elective bilateral salpingectomy or Salpingo-oophorectomy by vaginal Natural Orifice Transluminal Endoscopic Surgery approach
- Control group: Laparoscopic (Type: OTHER): Elective bilateral salpingectomy or Salpingo-oophorectomy by conventional laparoscopy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Corticosteroid Therapy for Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. They have three-months of persistent symptoms meeting criteria for chronic rhinosinusitis as defined by the Taskforce on Rhinosinusitis.~2. They have a CT-scan in our clinic or have a viewable recent (\< 3weeks prior to clinic visit) CT-scan with a Lund Mckay score of 6 or greater. A Lund Mckay score of 6 or greater is felt to be indicative of at least moderate CRS.~3. They do not have nasal polyps on initial clinic nasal endoscopy~4. They are willing to participate in a clinical study~5. They are between the ages of 18 to 80.~Exclusion Criteria:~1. They have a condition in which the use of systemic corticosteroids is contraindicated such as diabetes will be excluded.~2. They are unable to or unwilling to take the prescribed antibiotics or steroids will excluded.~3. They have been treated with a \> 3 week course of antibiotics and/or systemic steroids will also be excluded.~4. They have variants of chronic sinusitis known to be refractory to medical therapy such as Wegener's granulomatosis, primary ciliary dyskinesia or sarcoidosis.~5. They have sinusitis secondary to prior surgery, a dental procedure or anatomical variants.~6. They have nasal polyps on physical exam.~7. They are pregnant. Subjects who are possibly pregnant will be excluded based on history. Pregnancy testing is not standard of care for diagnostic imaging.~8. They have a Lund-Mckay score on CT scan of \< 6~9. They are \< 18 or \> 80 years old

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Prednisone (Type: ACTIVE_COMPARATOR): Oral steroid medication
- Topical Mometasone (Type: ACTIVE_COMPARATOR): Topical steroid medication

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy